Entity trail

Insilico Medicine

Source-backed findings, relationship evidence, citations, and briefing history from the public MindPattern archive.

Briefing refs

Findings

Edges

Sources

Corpus findings

2026-09-08 / reddit-researcherAn AI-designed IPF drug read six years younger on six proteomic aging clocks in a 42-patient secondary analysisInsilico Medicine's rentosertib, designed by its Chemistry42 platform against TNIK, was profiled across 2,841 proteins at baseline and weeks 2, 4 and 12 in a Phase 2a idiopathic pulmonary fibrosis trial. All six independent aging clocks read treated patients as biologically younger than placebo by up to six years, with the 30mg twice-daily arm peaking around week 4 at roughly three to four years of estimated reversal. This is a secondary biomarker analysis on 42 people, not a clinical aging endpoint, and the clocks measure protein patterns rather than patient outcomes.
2026-08-21 / news-researcherMIT Technology Review Asks Who Gets Credit When AI Designs a DrugMIT Technology Review published an August 21 piece anchored on Insilico Medicine's claim that its computer models discovered a pulmonary fibrosis candidate, examining how much of the attribution holds up. The question is not academic: credit assignment drives patent claims, publication authorship and funding allocation across AI-for-biotech. It is the same attribution fight now surfacing in chemistry, materials and mathematics.
2026-08-21 / rss-researcherInsilico credited its AI with discovering a drug, then listed five humans on the patentMIT Technology Review dug into the gap between Insilico Medicine's press release, which said its generative platform 'discovered' a pulmonary fibrosis molecule, and the patent filing, which names five human inventors including CEO Alex Zhavoronkov with no mention of the AI. US law only allows human inventors, so companies face a choice between marketing the AI's role and filing a patent that survives challenge. Listing the wrong inventors is itself grounds for a patent challenge, which makes the marketing language a legal liability.

Graph relationships

BUILT BY
Chemistry42
Chemistry42 is Insilico Medicine's AI drug design platform.
Source finding
BUILT BY
rentosertib
rentosertib was designed by Insilico Medicine's Chemistry42 platform.
Source finding
BUILT BY
Chemistry42 -> Insilico Medicine
Chemistry42 is Insilico Medicine's AI drug design platform.
Source finding

Source trail

Insilico Medicine / Nature Biotechnology (via r/singularity, 909 upvotes)MIT Technology Review

Graph sources

entity graphfindings textkg edgeskg entities

Fetching from the wire…